Octreotide
(Somatostatin)Phase 1Small molecule
Johnson & JohnsonSomatostatin is used to treat certain hormone-producing tumors and control severe diarrhea and flushing caused by specific cancers. It works by reducing the amount of hormones your body produces that cause these symptoms.[1] Octreotide is currently being investigated across 7 indications[3], with its most advanced program in Phase 1.[1]
Octreotide is one of 76 small molecule programs targeting Gastrointestinal hemorrhage. It is currently in Phase 1.
7
Indications
33
Total Trials
4
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
96 competitors in Liver Transplant
#DrugCompanyPhaseTrials
1Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Darbepoetin
BayerPhase 3
Prothrombin Complex Concentrate
CSL BehringPhase 3
Rezzayo
MMundipharma (China) Pharmaceutical Co. Ltd
Phase 3
Octreotide
Johnson & JohnsonPhase 1
Tacrolimus Pill
EEdward Geissler
Phase 3
Lenvima
EisaiPreclinical
Beyfortus
BeiGenePreclinical
Prostigmin
Merck & Co.Preclinical
Myfortic
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metabolism3 trials
Hypoglycemia2 trials
Liver Transplant2 trials
Hepatocellular Carcinoma2 trials
23 more indications
Gastrointestinal1 trial
Metabolic Consequences of Gastrointestinal Surgery
Terminated·—·N/A·NCT02836353·81 enrolled
Acute Kidney Injury1 trial
Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding
Completed·—·Phase 4·NCT04358016·54 enrolled
Gallbladder Carcinoma1 trial
Small Bowel Obstruction1 trial
Pancreaticoduodenectomy1 trial
Bleeding1 trial
Liver Resection1 trial
Pancreatitis1 trial
Gastrointestinal hemorrhage1 trial
Gastric Varices1 trial
Insulin Secretion1 trial
Acute Variceal Bleeding1 trial
Postoperative Pancreatic Fistula1 trial
Prostate Cancer1 trial
Gastric Cancer1 trial
Liver Failure1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Somatostatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Somatostatin Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company